toripalimab (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

Nasopharyngeal Carcinoma

Pending FDA approval for first-line treatment of advanced, recurrent, or metastatic nasopharyngeal carcinoma (NPC) in combination with gemcitabine and cisplatin

Also pending FDA approval as monotherapy for second-line or above treatment of recurrent or metastatic NPC after platinum-containing chemotherapy

Next:

Pharmacology

Mechanism of Action

Monoclonal antibody to programmed cell death-1 protein (PD-1); blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2

PD-1 and PD-L1

  • PD-1 and related target PD-ligand 1 (PD-L1) are expressed on the surface of activated T-cells under normal conditions; PD-1/PD-L1 interaction inhibits immune activation and reduced T-cell cytotoxic activity when bound
  • This negative feedback loop is essential for maintaining normal immune responses and limits T-cell activity to protect normal cells during chronic inflammation
  • Tumor cells may circumvent T-cell-mediated cytotoxicity by expressing PD-L1 on the tumor itself or on tumor-infiltrating immune cells, resulting in the inhibition of immune-mediated killing of tumor cells
Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.